CHRS
Coherus Oncology, Inc.
CHRS offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over CHRS overall, supported by stronger fundamentals and lower modeled downside.
CHRS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
CHRS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CHRS PE Valuation
CHRS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CHRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect CHRS's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CHRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.00 | -172% |
| Q2 2026 | -$1.06 | -166% |
| Q1 2026 | $1.64 | +$2.71 |
| Q4 2025 | $1.43 | +472% |
| Q3 2025 | $1.39 | +$1.43 |
| Q2 2025 | $1.61 | +$1.97 |
| Q1 2025 | -$1.07 | -$0.33 |
| Q4 2024 | $0.25 | +$2.78 |
CHRS has swung to a loss: it lost $1.00 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CHRS on earnings quality, reporting a profit while its opponent remains loss making.
CHRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14.3M | +23% |
| Q2 2026 | $14.3M | +40% |
| Q1 2026 | $12.3M | +62% |
| Q4 2025 | $12.7M | -76% |
| Q3 2025 | $11.6M | -84% |
| Q2 2025 | $10.3M | -84% |
| Q1 2025 | $7.6M | -90% |
| Q4 2024 | $54.1M | -41% |
CHRS's revenue is recovering but still below its 2020 peak: $14M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -236% | +147 points |
| Q2 2026 | -226% | +218 points |
| Q1 2026 | -294% | +304 points |
| Q4 2025 | -360% | -282 points |
| Q3 2025 | -383% | -374 points |
| Q2 2025 | -444% | -412 points |
| Q1 2025 | -598% | -543 points |
| Q4 2024 | -78% | -2.7 points |
CHRS's operating margin was −236% last quarter, up 147 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CHRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CHRS on profitability, with a higher operating margin.
CHRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34M | +$12.3M |
| Q2 2026 | -$62.1M | -$15.5M |
| Q1 2026 | -$57.9M | -$32.1M |
| Q4 2025 | -$19.7M | -169% |
| Q3 2025 | -$46.3M | +$15.7M |
| Q2 2025 | -$46.6M | -178% |
| Q1 2025 | -$25.8M | +$20.9M |
| Q4 2024 | $28.6M | +$41.6M |
CHRS has burned cash in most quarters: −$174M over the past year, against −$90M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CHRS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CHRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +154K shares |
| 1 year | +34% | +38.9M shares |
| 3 years | +78% | +67.7M shares |
| 5 years | +105% | +79.4M shares |
| Available history | +112% | +81.8M shares |
CHRS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CHRS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | -2.9x | Net Cash |
| Q3 2020 | -1.1x | Net Cash |
| Q2 2020 | -0.7x | Net Cash |
| Q1 2020 | -0.7x | Net Cash |
| Q4 2019 | -0.9x | Net Cash |
CHRS has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CHRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 3.7 | Oversold |
CHRS's weekly RSI is 24 (oversold) and its Stochastic is 4 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CHRS PE vs Healthcare Sector
| Metric | CHRS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CHRS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CHRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.94 | 43% below |
| 20 week MA | $1.21 | 55% below |
| 50 week MA | $1.46 | 63% below |
| 100 week MA | $1.30 | 58% below |
| 200 week MA | $2.34 | 77% below |
CHRS is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CHRS on trend strength, trading above more of its moving averages.
CHRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $17.4 | -4.7% |
| 2021 | $17.4 | $17.8 | +2.5% |
| 2022 | $17.8 | $6.45 | -64% |
| 2023 | $6.45 | $3.33 | -48% |
| 2024 | $3.33 | $1.49 | -55% |
| 2025 | $1.49 | $1.33 | -11% |
| 2026 YTD | $1.33 | $0.54 | -59% |
CHRS has finished four years in a row lower, and it's down 59% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CHRS on returns for 2026, with the stronger performance.